Cargando…
Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review
Immune checkpoint inhibitors (ICIs) have been approved for patients with advanced non-small-cell lung cancer (NSCLC), regardless of histology. However, histologic subtypes of NSCLC may influence treatment outcomes of ICIs. We conducted this meta-analysis to investigate if there is difference in surv...
Autores principales: | Kim, Bum Jun, Kim, Jung Han, Kim, Hyeong Su |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584287/ https://www.ncbi.nlm.nih.gov/pubmed/28881686 http://dx.doi.org/10.18632/oncotarget.17213 |
Ejemplares similares
-
Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017) -
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017) -
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017) -
Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017) -
Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)